Company News

Share this article:

Abbott opened a nutrition product manufacturing facility in Singapore, in order to meet increasing regional demand for its pediatric products, including Similac, according to company statement. The facility represents the company's largest nutrition investment to date, at $300 million. According to Abbott, the facility will serve up to one million Asian infants and children each year.

 

FDA halted the review of all NDA's received from a Ranbaxy Laboratories plant in India, after discovering falsified data. In a letter to Ranbaxy, CDER director Janet Woodcock said the findings “indicate a pattern and practice of submitting untrue statements of material fact and other wrongful conduct, which raise significant questions regarding the reliability of the data and information contained in applications (pending and approved) that [Ranbaxy] has filed with the agency and which contain data developed at the Ranbaxy Laboratories, Paonta Sahib site.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.